Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Drug Pricing Bill May Make Six-Month ANDA Review Slower Than Eight-Month Review

Feb 03 2017

• By Derrick Gingery

Capitol House

Related Content

Priority Review Voucher Program For Rare Pediatric Diseases Extended As FDA Lowers Fee

Sep 29 2016

ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal

Sep 24 2016

Review Voucher Program For Rare Pediatric Diseases Should Not Be Reauthorized, US FDA Says

Mar 03 2016

GDUFA Performance Goals For Fiscal Years 2013-2017

Dec 12 2011

Trump Promises Changes To 'A Lot Of Rules' At US FDA

Feb 01 2017

PDUFA VI: Industry Ready For 'Hard Sell' To Keep Agreement Intact

Dec 20 2016

US FDA May Find Relief From Trump's Hiring Freeze

Feb 02 2017

Generic User Fee Renewal Talks Faced 'Buyer's Remorse' From GDUFA I

Oct 27 2016

Additional Topics

United States Generic Drugs Pricing Debate Regulation Legislation BioPharmaceutical

More from Generics

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.